Abstract：Objective: To evaluate the efficacy and safety of anlotinib in the treatment of advanced non-small cell lung cancer. Methods: The randomized controlled trial (RCT) was searched from PubMed, EMBASE, Web of Science, Cochrane Library, Wanfang, VIP, CNKI, SinoMed and other databases from January, 2018 to March, 2020. Two researchers independently screened and evaluated the literature quality according to the inclusion and exclusion criteria, Revman 5.3 statistical software was used for meta-analysis of the included randomized controlled trials. Results: A total of 8 randomized controlled trials involving 784 patients, 474 patients in the experimental group and 310 patients in the control group were included. The results of meta-analysis showed that anlotinib could prolong progression free survival (PFS) [HR = 0.34,95% CI (0.30,0.39), P<0.00001] and overall survival (OS) [HR = 0.73, 95% CI (0.63, 0.85), P<0.0001]. Anlotinib also has advantages in improving disease control rate (DCR) [RR = 1.66, 95% CI (1.06, 2.58), P=0.03],objective response rate(ORR) [RR = 2.03, 95% CI (1.06, 3.58), P=0.03] and the adverse reactions were controllable. Conclusion: Compared with placebo or systemic chemotherapy, anlotinib can effectively improve the disease control rate and objective efficiency of advanced non-small cell lung cancer, and prolong the median progression free survival and median overall survival of patients. However, the number of included literature is small, the number of samples is small, and the analysis results indicate that the heterogeneity is large, so clinical randomized controlled trials with larger sample sizes and higher quality are still needed to further demonstrate the results.
[1] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer Clin,2018,68(6):394~424. [2] Yoon SM,Shaikh T,Hallman M.Therapeutic management options for stage III non-small cell lung cancer[J].World Clin Oncol,2017,8(1):1~20. [3] Allemani C,Matsuda T,Di Carlo V,et al.Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J].Lancet,2018,391(10125):1023~1075. [4] Rusch VW,Chansky K,Kindler HL,et al.The IASLC mesothelioma staging project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma[J].Thorac Oncol,2016,11(12):2112~2119. [5] 陈小岑.肺癌患者放疗不良反应及其影响因素与症状群建立的研究[D].天津医科大学,2014. [6] 王睿晴,张艳华.抗肿瘤分子靶向药物安罗替尼的临床研究进展[J].中国新药杂志,2018,27(23):2770~2774. [7] 斯晓燕,王汉萍,张晓彤,等.安罗替尼治疗晚期非小细胞肺癌16例临床分析[J].中华内科杂志,2018,57(11):830~834. [8] 高亭,何小鹏,李敏,等.安罗替尼一线治疗晚期非小细胞肺癌的临床疗效观察[J].浙江医学,2019,41(23):2543~2545. [9] 戴秀梅,张有为,韩亮,等.安罗替尼治疗晚期非小细胞肺癌的临床效果[J].中国医药导报,2019,16(32):95~98. [10] 辛涛,金发光,刘伟,等.盐酸安罗替尼胶囊治疗晚期非小细胞肺癌的临床研究[J].中华肺部疾病杂志,2018,11(5):559~562. [11] 徐寿华,杜海燕.安罗替尼三线治疗晚期非小细胞肺癌的临床研究[J].中国肿瘤临床与康复,2020,27(2):214~216. [12] 皇甫娟,李文永,张慧辉.安罗替尼胶囊治疗晚期非小细胞肺癌对患者VEGF水平及生存期的影响[J].实用癌症杂志,2020,35(03):360~362. [13] Han B,Li K,Zhao Y,et al.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre,randomised phase II trial (ALTER0302)[J].Br Cancer,2018,118(5):654~661. [14] Han B,Li K,Wang Q,et al.Effect of anlotinib as a third-Line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J].JAMA Oncol,2018,4(11):1569~1575. [15] Siegel RL,Miller KD,Jemal A.Cancer statistics,2019[J].CA Cancer Clin,2019,69(1):7~34. [16] Cronin KA,Lake AJ,Scott S,et al.Annual report to the nation on the status of cancer,part I: national cancer statistics[J].Cancer,2018,124(13):2785~2800. [17] Lin B,Song X,Yang D,et al.Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2,PDGFRβ and FGFR1[J].Gene,2018,654:77~86. [18] Xie C,Wan X,Quan H,et al.Preclinical characterization of anlotinib,a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor[J].Cancer Sci,2018,109(4):1207~1219. [19] Hayman SR,Leung N,Grande JP,et al.VEGF inhibition,hypertension,and renal toxicity[J].Curr Oncol Rep,2012,14(4):285~294. [20] Rogiers A,Wolter P,Op de Beeck K,et al.Shrinkage of thyroid volume in sunitinib-treated patients with renal-cell carcinoma: a potential marker of irreversible thyroid dysfunction[J].Thyroid,2010,20(3):317~322.
2021, Vol. 27 
冀公网安备13080202000677号